MedTrace Logo

3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion

NCT07295054 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-05-11

No results posted yet for this study

Summary

Intrauterine device (IUD) insertion is a common contraceptive procedure often associated with moderate to severe pain, particularly among nulliparous individuals. Current pain management strategies, such as over-the-counter analgesics, are frequently inadequate. Methoxyflurane, a short-acting, self-administered inhaled analgesic, has been shown to provide rapid and effective pain relief in acute and procedural settings. This study aims to evaluate whether 3 mL of inhaled Methoxyflurane (via Penthrox inhaler) improves patient satisfaction by reducing pain and anxiety during IUD insertion.

Conditions

  • IUD

Interventions

DRUG

Methoxyflurane

3 mL of Methoxyflurane via a handheld inhaler

DRUG

Saline

3 mL of Normal Saline via an identical placebo handheld inhaler

Sponsors & Collaborators

  • Women's College Hospital

    lead OTHER

Principal Investigators

  • Lauren Scott, NP · Women's College Hospital

  • Karim Ladha, MD · Women's College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-27
Primary Completion
2026-12-31
Completion
2027-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07295054 on ClinicalTrials.gov